City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  48  Clinical trial(s) found  (Page 1 of 2 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for Brain and Nervous System Cancer:
COH Protocol Number: 15448

Principal Investigator: Jana Portnow, MD
Sponsor: Institutional

Title:  Single Subject Protocol for SA for Treatment with Rindopepimut (CDX-110) and Bevacizumab

COH Protocol Number: 15347

Principal Investigator: Behnam Badie, MD
Sponsor: Institutional

Title:  Single Patient Treatment with Intraventricular Cellular Immunotherapy Using Autologous IL13(EQ)BB?/CD19t+ Tcm-Enriched T Cells for a Patient with Recurrent Multifocal Malignant Glioma (UPN 109)

COH Protocol Number: 15129 ClinicalTrials.gov Number: NCT02017964

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ACNS1221:A Phase II Study For The Treatment Of Non-Metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years Of Age

COH Protocol Number: 14221 ClinicalTrials.gov Number: NCT02176967

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

COH Protocol Number: 13401 ClinicalTrials.gov Number: NCT02015819

Principal Investigator: Jana Portnow, MD
Sponsor: Institutional

Title:  A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination with Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas

COH Protocol Number: 13384 ClinicalTrials.gov Number: NCT02208362

Principal Investigator: Behnam Badie, MD
Sponsor: Institutional

Title:  Phase I Study of Cellular Immunotherapy Using Central Memory Enriched T Cells Lentivirally Transduced to Express an IL13Ra2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients with Recurrent/Refractory Malignant Glioma

COH Protocol Number: 13162 ClinicalTrials.gov Number: NCT01553149

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ACNS1022: A Phase II Randomized Trial of Lenalidomide (NSC #703813, IND #70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

COH Protocol Number: 13140 ClinicalTrials.gov Number: NCT01096368

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ACNS0831:Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma ages 1-21 years

COH Protocol Number: 07074

Principal Investigator: Christine Brown, PH.D.
Sponsor: Institutional

Title:  Isolation of Brain Tumor Cancer Stem Cells from Discard Primary Glioma Tissue

COH Protocol Number: 01094

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ANBL00B1: Neuroblastoma Biology Studies

The following studies are available for many cancer types, including Brain and Nervous System Cancer:
COH Protocol Number: 15320

Principal Investigator: Vincent Chung, MD
Sponsor: Institutional

Title:  The Total Cancer Care Protocol: A Lifetime Partnership with Patients of the City of Hope

COH Protocol Number: 15293 ClinicalTrials.gov Number: NCT02568267

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

COH Protocol Number: 15268 ClinicalTrials.gov Number: NCT02628067

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)

COH Protocol Number: 15233 ClinicalTrials.gov Number: NCT02091141

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab Erlotinib, Vemurafenib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive or Response to One of these Agents

COH Protocol Number: 15172

Principal Investigator: Vinod Pullarkat, MD
Sponsor: Institutional

Title:  A Pilot Study of Candidate Biomarkers and Clinical Correlates of Chronic Graft Versus Host Disease

COH Protocol Number: 15161 ClinicalTrials.gov Number: NCT02517034

Principal Investigator: Arti Hurria, MD
Sponsor: Institutional

Title:  Advancing Screening and Treatment for Older Patients with Cancer

COH Protocol Number: 15025 ClinicalTrials.gov Number: NCT02408406

Principal Investigator: Matthew Loscalzo, MSW
Sponsor: NCI Approved External Peer Review

Title:  PatientCareAnywhere: Patient Support and Empowerment Across the Care Continuum

COH Protocol Number: 15005 ClinicalTrials.gov Number: NCT00697632

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  Open-Label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Patients with Advanced Malignancies

COH Protocol Number: 14302 ClinicalTrials.gov Number: NCT02345798

Principal Investigator: Jae Kim, MD
Sponsor: Institutional

Title:  Preparing Patients and Informal Caregivers for Lung Surgery: Pilot Study of a Video-Assisted Intervention to Enhance Post-Operative Recovery

COH Protocol Number: 14299 ClinicalTrials.gov Number: NCT02301104

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients with Advanced Solid Tumors and Varying Degrees of Hepatic Impairment

COH Protocol Number: 14285 ClinicalTrials.gov Number: NCT02301117

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients with Advanced Solid Tumors and Varying Degrees of Renal Impairment

COH Protocol Number: 14276 ClinicalTrials.gov Number: NCT02243592

Principal Investigator: Robert Chen, MD
Sponsor: NCI Approved External Peer Review

Title:  Exceptional Responders Pilot Study: Molecular Profiling of Tumors from Cancer Patients who are Exceptional Responders

COH Protocol Number: 14265 ClinicalTrials.gov Number: NCT01625234

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer

COH Protocol Number: 14262 ClinicalTrials.gov Number: NCT01004224

Principal Investigator: Sumanta Pal, MD
Sponsor: Industrial

Title:  A Phase I, Open-Label, Multi-Center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients with Advanced Solid Malignancies

COH Protocol Number: 14238 ClinicalTrials.gov Number: NCT02293954

Principal Investigator: Jeffrey Wong, MD
Sponsor: Institutional

Title:  Pilot Study: Detection of Carcinomas Using 64Cu-Labeled M5A Antibody to Carcinoembryonic Antigen (CEA)

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.